NanoString Technologies soars after landing FDA 510k clearance for its Prosigna diagnostic test

|About: NanoString Technologies (NSTG)|By:, SA News Editor

NanoString Technologies (NSTG +41%) soars after receiving FDA 510(k) clearance for its Prosigna diagnostic test.

The test uses the gene expression profile of cells found in breast cancer tissue to assess a patient's risk of distant recurrence of disease.

Prosigna is the company's first FDA-approved in vitro diagnostic assay, and CEO Brad Gray notes the approval "marks a milestone for NanoString and is an important step forward in the treatment of breast cancer."